Anti-VLA-4 related assays
AssigneeBiogen MA Inc.
InventorsTatiana Plavina, Paula S. Hochman, Michaela Lerner
Life of this patent
Estimating the term…
Abstract
Methods and apparatus for assaying the level of analytes in a sample, related to VLA-4, are disclosed. A method of decreasing the level of an anti-integrin antibody in a subject is described including a) contacting a biological sample from a subject with a detectable capture agent associated with a substrate, wherein the capture agent can bind an anti-integrin antibody in the sample; b) detecting binding of the capture agent with the level of the anti-integrin antibody; and c) treating the subject with plasma exchange until the level of the anti-integrin antibody in the sample reaches a predetermined level.
Claims40
A method of assaying the efficacy of a treatment, the method comprising:
- a) contacting a biological sample obtained from a subject undergoing treatment with an anti-alpha4 integrin antibody with a capture agent associated with a substrate, wherein the capture agent can bind an anti-anti-alpha4 integrin antibody in the biological sample to form a complex, and wherein the substrate is a portion of a lateral flow immunochromatographic system comprising, in order of flow, a label zone, a sample receiving zone, and a test zone;
- and
- b) detecting the binding of the capture agent to the anti-anti-alpha4 integrin antibody with a secondary agent that binds to said complex within the lateral flow immunochromatographic system and correlating the binding of the capture agent to the level of the anti-anti-alpha4 integrin antibody to determine the efficacy of the treatment, wherein the capture agent is an antibody or an antigen binding fragment thereof and the secondary agent comprises one or more labeled antibodies associated with the substrate in the label zone upstream of the sample receiving zone.
D) A kit for assaying the level of an anti-anti-alpha4 integrin antibody in a biological sample obtained from a subject, comprising:
- a) a tester comprising:
- a lateral flow immunochromatographic system comprising a substrate comprising, in order of flow, a label zone, a sample receiving zone, and a test zone, wherein
- the test zone is downstream of the sample receiving zone comprises a capture agent associated with the substrate, wherein the capture agent is an antibody or antigen binding fragment thereof that binds to the anti-anti-alpha4 integrin antibody in the biological sample to form a complex, and
- the label zone is located upstream of the sample receiving zone comprises a secondary agent associated with the substrate, wherein the secondary agent comprises one or more labeled antibodies capable of binding to said complex within the lateral flow immunochromatographic system;
- and
- b) a chase buffer.
Dependencies are inferred from the claim text.